Reported about 1 month ago
The FDA has paused Novavax's flu-COVID vaccine trial following a report of a patient experiencing motor neuropathy linked to a vaccine from a previous phase two trial. Consequently, Novavax's stock has dropped nearly 20%.
Source: YAHOO